The Sialic Acid Binding Immunoglobulin Type Lectin pipeline drugs market research report outlays comprehensive information on the Sialic Acid Binding Immunoglobulin Type Lectin targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Sialic Acid Binding Immunoglobulin Type Lectin pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Central Nervous System, Immunology, and Ophthalmology which include the indications B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Alzheimer’s Disease, Multiple Sclerosis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Ophthalmology, and Glaucoma. It also reviews key players involved in Sialic Acid Binding Immunoglobulin Type Lectin targeted therapeutics development with respective active and dormant or discontinued products.
The Sialic Acid Binding Immunoglobulin Type Lectin pipeline targets constitutes close to 125 molecules. Out of which, approximately 93 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/ CTA Filed, Preclinical, and Discovery stages are 2, 1, 18, 16, 5, 2, 36, and 12 respectively. Similarly, the universities portfolio in Phase II, Phase I, Phase 0, and Preclinical comprises 16, 10, 1, and 5 molecule.
Sialic Acid Binding Immunoglobulin Type Lectin overview
SIGLEC are transmembrane proteins that act as cell surface receptors for a variety of sialylated glycoconjugates. They are type 1 membrane proteins containing an amino-terminal V-set immunoglobulin domain that mediates sialic-acid recognition and varying numbers of C2-set immunoglobulin domains.
For a complete picture of Sialic Acid Binding Immunoglobulin Type Lectin’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
